ArticleTranslational vision science & technology2026
Characterization of Rcbtb1 Knockout Mice and Evaluation of AAV2-RCBTB1 Gene Replacement Therapy.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Biallelic pathogenic variants in the RCC1 and BTB domain-containing protein 1 (RCBTB1) gene cause an adult-onset retinal dystrophy. Here, we generated a knockout mouse model of RCBTB1 deficiency for the evaluation of RCBTB1 gene therapy. Methods: Rcbtb1-knockout (KO) mice were generated with a homozygous deletion removing exons 2 and 3 of Rcbtb1. Wild-type (WT) and Rcbtb1-KO mice were assessed by optical coherence tomography and electroretinography at 3, 8, and 14 months of age. Retinal ultrastructure was assessed by transmission electron microscopy. Subretinal injections of adeno-associated virus 2 (AAV2)-RCBTB1 or AAV2-enhanced green fluorescent protein (EGFP) vector were performed at 2 months, and mice were analyzed at 8 months. Retinal gene expression was assessed by quantitative PCR and immunohistochemistry. Results: Retinal Rcbtb1 expression was absent in Rcbtb1-KO mice. Eight-month-old Rcbtb1-KO mice showed reduced outer retinal thickness compared with WT mice. Ultrastructural analysis demonstrated increased mitochondrial damage in retinal pigment epithelial cells and increased frequencies of mitochondria with oxidative inclusions in photoreceptor inner segments in 8-month-old Rcbtb1-KO mice. Degenerating retinal pigment epithelium (RPE) and photoreceptors were observed in Rcbtb1-KO mice. Bruch's membrane appeared thicker in Rcbtb1-KO mice and contained druse-like deposits. Treatment with AAV2-RCBTB1 induced sustained RCBTB1 expression and preserved outer retinal thickness in 8-month-old Rcbtb1-KO mice. Conclusions: Rcbtb1-KO mice showed accelerated outer retinal thinning, increased mitochondrial damage in the RPE, and photoreceptor apoptosis. AAV2-RCBTB1 vectors induced long-term retinal expression of RCBTB1 and prevented retinal thinning in Rcbtb1-KO mice. Translational Relevance: Rcbtb1-KO mice provide a useful animal model for modeling RCBTB1 deficiency and preclinical screening of novel treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.